Rilonacept

Rilonacept
Klinički podaci
Drugs.comMonografija
Način primeneSubkutano
Identifikatori
CAS broj501081-76-1 Зелена квачицаДа
ATC kodL04AC04 (WHO)
DrugBankDB06372 Зелена квачицаДа
ChEMBLCHEMBL1201830 Зелена квачицаДа

Rilonacept, takođe poznat kao IL-1 Trap i Arcalyst, je inhibotor interleukina 1.[1][2][3][4][5][6]

Reference

  1. ^ "The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study " Oct 2009
  2. ^ Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP: Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. Hoffman, H. M.; Throne, M. L.; Amar, N. J.; Cartwright, R. C.; Kivitz, A. J.; Soo, Y.; Weinstein, S. P. (2012 Oct). „Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: Results of a 72-week open-label extension study”. Clinical Therapeutics. 34 (10): 2091—103. PMID 23031624. doi:10.1016/j.clinthera.2012.09.009.  Проверите вредност парамет(а)ра за датум: |date= (помоћ).. Epub 2012 Sep 29.
  3. ^ Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V: Role of Interleukin-1 Inhibitors in the Management of Gout. Pharmacotherapy. 3.Tran, T. H.; Pham, J. T.; Shafeeq, H.; Manigault, K. R.; Arya, V. (2013 Apr). „Role of interleukin-1 inhibitors in the management of gout”. Pharmacotherapy. 33 (7): 744—753. PMID 23553601. doi:10.1002/phar.1265.  Проверите вредност парамет(а)ра за датум: |date= (помоћ).
  4. ^ Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. Hawkins, P. N.; Lachmann, H. J.; McDermott, M. F. (2003 Jun 19). „Interleukin-1-receptor antagonist in the Muckle-Wells syndrome”. The New England Journal of Medicine. 348 (25): 2583—4. PMID 12815153. doi:10.1056/NEJM200306193482523.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  5. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  6. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 

Literatura

Spoljašnje veze

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.